Medical Therapy. Efficacy or Lack of Efficacy

Nintedanib preserves lung growth and prevents pulmonary hypertension in a hyperoxia-induced lung injury model

Kathy L. Ding, Caroline Smith, Gregory Seedorf, Steven H. AbmanUniversity of Colorado School of Medicine.United States Pediatric ResearchPediatr Res 2024; DOI: 10.1038/s41390-024-03562-0 AbstractBackground: Bronchopulmonary dysplasia (BPD), the chronic lung disease associated with prematurity, is characterized by poor alveolar and vascular growth, interstitial fibrosis, and pulmonary hypertension (PH). Although multifactorial in origin, the pathophysiology of BPD is partly […]

Nintedanib preserves lung growth and prevents pulmonary hypertension in a hyperoxia-induced lung injury model Read More »

Immunoregulatory Macrophages Modify Local Pulmonary Immunity and Ameliorate Hypoxic Pulmonary Hypertension

Angelez Fernandez-Gonzalez, Amit Mukhia, Janhavi Nadkarni, Gareth R. Willis, Monica Reis, Kristjan Zhumka, Sally Vitali, Xianlan Liu, Alexandra Galls, S. Alex Mitsialis, Stella KourembanasBoston Children’s Hospital and Harvard Medical School.United States Arteriosclerosis Thrombosis and Vascular BiologyArterioscler Thromb Vasc Biol 2024; DOI: 10.1161/ATVBAHA.124.321264 AbstractBackground: Macrophages play a significant role in the onset and progression of vascular disease in

Immunoregulatory Macrophages Modify Local Pulmonary Immunity and Ameliorate Hypoxic Pulmonary Hypertension Read More »

A Belgian consensus on sotatercept for the treatment of pulmonary arterial hypertension

Jean-Luc Vachiéry, Catharina Brlge, Bjorn Cools, An Damen, Fabian Demeure, Michel De Pauw, Céline Dewachter, Daniel De Wolf, Laurence Gabriel, Laurent Godinas, Julien Guiot, Steven Haine, Mathias Leys, Marc Meysman, Anne-Catherine-Pouleur, Davis Ruttens, Els Vansteenkiste, Wendy Vansteenkiste, Thierry Weber, Gil Wirtz, Marion DelcroixHôpital Universitaire de Bruxelles Erasme. University Hospitals of Leuven and University of Leuven.

A Belgian consensus on sotatercept for the treatment of pulmonary arterial hypertension Read More »

Metabolic gene therapy in a canine with pulmonary hypertension secondary to degenerative mitral valve disease

Michael G. Katz, Dan G. Ohad, Philip Putter, Nataly Shtraizent, Ehud Shahar, Smadar Tal, Efrat EliyahuIcahn School of Medicine at Mount Sinai. Veterinary Teaching Hospital of the Koret School of Veterinary Medicine and Hebrew University of Jerusalem. Spot On Veterinary Hospital. Senex. Frezent Biological Solutions. Tel-Hai College. Migal-Galilee Research Institute. United States and Israel Frontiers in Veterinary MedicineFront Vet Med 2024; 11: DOI: 10.3389/fvets.2024.1415030 AbstractMyxomatous

Metabolic gene therapy in a canine with pulmonary hypertension secondary to degenerative mitral valve disease Read More »

The effects of standardized intravenous treprostinil in pulmonary arterial hypertension patients after total cavo-pulmonary connection procedure

Xiaofeng Wang, Shilin Wang, Ruihuan Shen, Zhongyuan Lu, Xu WangFuwai Hospital, Beijing Hospital and Chinese Academy of Medical Sciences and Peking Union Medical College.China European Journal of Medical ResearchEur J Med Res 2024; 29: DOI: 10.1186/s40001-024-02077-y AbstractObjective: Total cavo-pulmonary connection (TCPC) is a palliative treatment for single ventricular malformations. For high-risk patients (preoperative mean pulmonary arterial pressure,

The effects of standardized intravenous treprostinil in pulmonary arterial hypertension patients after total cavo-pulmonary connection procedure Read More »

Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial Hypertension

Marius M. Hoeper, David B. Badesch, H. Ardeschir Ghofrani, J. Simon R. Gibbs, Mardi Gomberg-Maitland, Valerie V. McLaughlin, Ioana R. Preston, Rogerio Souza, Aaron B. Waxman, Ekkehard Grünig, Grzegorz Kopeć, Gisela Meyer, Karen M. Olsson, Stephan Rosenkranz, Yayun Xu, Barry Miller, Marcie Fowler, John Butler, Jeorg Koglin, Janethe de Oliveira Pena, and Marc Humbert, for

Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial Hypertension Read More »

Patterns and Outcomes of Epoprostenol Use in Infants with Congenital Diaphragmatic Hernia Requiring Extracorporeal Life Support

Nikhil R. Shah, Keerthi Burgi, Dimitra M. Lotakis, Mary K. Olive, Amanda D. McCormick, Erin E. Perrone, Joseph T. Church, George B. MychaliskaC.S. Mott Children’s Hospital, Michigan Medicine and University of Michigan Medical School. United States Journal of PediatricsJ Pediatr 2024; DOI: 10.1016/j.jpeds.2024.114286 AbstractObjective: To describe our experience utilizing epoprostenol for pulmonary hypertension (PH) in infants with

Patterns and Outcomes of Epoprostenol Use in Infants with Congenital Diaphragmatic Hernia Requiring Extracorporeal Life Support Read More »

Covid-19-induced pulmonary hypertension in children, and the use of phosphodiesterase-5 inhibitors

Herlina Dimiati Dimas Arya Umara, Iflan NaufalUniversitas Syiah Kuala,Indonesia F1000 ResearchF1000Res 2022; DOI: 10.12688/f1000research.53966.2 AbstractRespiratory tract infection caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) first occurred in Wuhan, China, in December 2019 and was declared as a pandemic by WHO. The interaction between the 2019 coronavirus disease (COVID-19) and pulmonary hypertension (PH) in children

Covid-19-induced pulmonary hypertension in children, and the use of phosphodiesterase-5 inhibitors Read More »

Embracing the challenges of neonatal and paediatric pulmonary hypertension

Dunbar Ivy, Erika B. Rosenzweig, Steven H. Abman, Maurice Beghetti, Damien Bonnet, Johannes Menno Douwes, Alessandra Manes, RolfM.F.BergerUniversity of Colorado School of Medicine and Children’s Hospital Colorado. Maria Fareri Children’s Hospital at WMC Health and New York Medical College of Touro University. Geneva University Hospital and University of Geneva. Necker Hospital for Sick Children. Beatrix

Embracing the challenges of neonatal and paediatric pulmonary hypertension Read More »

Intravenous magnesium sulfate in pulmonary hypertension of the newborn: a systematic review

G. Cuttone, C. Minardi, G. Baronti, C. Zanza, Y. Longhitano, L. La ViaASP Trapani.Italy European Review for Medical and Pharmacological SciencesEur Rev Med Pharmacol Sci 2024; DOI: 10.26355/eurrev_202408_36637 AbstractObjective: Pulmonary hypertension in the newborn (PPHN) is a significant clinical condition characterized by elevated pulmonary artery pressures, leading to serious health consequences. Magnesium sulfate, known for its vasodilatory

Intravenous magnesium sulfate in pulmonary hypertension of the newborn: a systematic review Read More »

Scroll to Top